Mounjaro vs Zepbound: Same Drug, Different Labels Explained
Mounjaro and Zepbound are both tirzepatide. Compare FDA approvals, dosing, insurance, and which brand name to ask your doctor about for weight loss.
| Dimension | tirzepatide | tirzepatide | Notes |
|---|---|---|---|
| Active Ingredient | Tirzepatide | Tirzepatide | Same molecule. Different brand names for different indications. |
| FDA Indication | Type 2 Diabetes | Chronic Weight Management | Mounjaro for T2D. Zepbound for obesity/overweight. |
| Max Dose | 15 mg/week | 15 mg/week | Same dose range for both brands. |
| Insurance | Better T2D coverage | Weight loss coverage growing | Mounjaro often easier for insurance. Zepbound weight management coverage expanding. |
Learn more about each peptide
Tirzepatide
Tirzepatide is a dual GIP/GLP-1 receptor agonist that has shown greater weight loss than semaglutide in head-to-head trials. It is sold under the brand names Mounjaro (diabetes) and Zepbound (weight management).
Tirzepatide
Tirzepatide is a dual GIP/GLP-1 receptor agonist that has shown greater weight loss than semaglutide in head-to-head trials. It is sold under the brand names Mounjaro (diabetes) and Zepbound (weight management).
More comparisons
Weekly peptide research updates
New studies, GLP-1 news, protocol insights, and weight loss data — delivered every week. Free. No spam.
Reviewed by Fat Man in the Arena · Updated March 2026
Medical Disclaimer: This comparison is for informational purposes only. Individual responses vary. Always consult a qualified healthcare provider before starting any peptide protocol.